表紙
市場調査レポート

Alnylam Pharmaceuticals, Inc.:パイプライン製品の分析

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224581
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
Alnylam Pharmaceuticals, Inc.:パイプライン製品の分析 Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年07月27日 ページ情報: 英文 88 Pages
概要

Alnylam Pharmaceuticals, Inc.は、RNA干渉法(RNAi)に基づいた新規治療薬の創薬・開発・販売に特化したバイオ医薬品企業です。同社では現在、「Alnylam 5x15」計画を推進し、遺伝子要因による疾患向けのRNAiベースの治療薬の開発に取り組んでいます。

当レポートでは、米国のバイオ医薬品企業、Alnylam Pharmaceuticals, Inc.(Alnylam)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

Alnylam Pharmaceuticals, Inc.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • パイプライン製品:単剤治療薬
  • パイプライン製品:アウトライセンス製品
    • アウトライセンス製品/併用治療モダリティ

パイプライン製品の概要

  • 後期段階のパイプライン製品
    • 第III相製品/併用治療モダリティ
  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ
    • 創薬段階の製品/併用治療モダリティ

薬剤のプロファイル

  • patisiran
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • ALN-TTRSC
  • asvasiran sodium
  • ALN-AT3
  • ALN-PCS02
  • ALN-PCSsc
  • ALN-TTR-01
  • ALN-VSP
  • ALN-AAT
  • ALN-ANG
  • ALN-APC
  • ALN-AS1
  • ALN-CC5
  • ALN-HPN
  • ALN-HTT
  • ALN-TMP
  • がん・ウイルス性感染症向け樹状細胞ワクチン
  • LNP-dsP21-322-2'F
  • パーキンソン病向けRNAi治療薬
  • SIRNA-034
  • 奇病向けマイクロRNA

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

企業のステートメント

事業所および子会社

  • 本社
  • その他の事業所・子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08097CDB

Summary

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
  • The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alnylam Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alnylam Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alnylam Pharmaceuticals, Inc. Snapshot
    • Alnylam Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alnylam Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alnylam Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PCSsc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-CC5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-GO1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HBV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TTRsc02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-VSP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AC3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AGT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PDL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HDV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Hepatic Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alnylam Pharmaceuticals, Inc. - Dormant Projects
  • Alnylam Pharmaceuticals, Inc. - Company Statement
  • Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alnylam Pharmaceuticals, Inc., Key Information
  • Alnylam Pharmaceuticals, Inc., Key Facts
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase III, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase II, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase I, 2016
  • Alnylam Pharmaceuticals, Inc. - Preclinical, 2016
  • Alnylam Pharmaceuticals, Inc. - Discovery, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Alnylam Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top